With 3.55 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.14 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $37.6053 whereas the lowest price it dropped to was $36.16. The 52-week range on BRKR shows that it touched its highest point at $84.90 and its lowest point at $34.10 during that stretch. It currently has a 1-year price target of $58.46. With its current market cap of 5.50 billion, BRKR has annualized dividend of $0.20 while the current yield stands at 0.55%. BRKR paid its most recent dividend on 1742169600, while the ex-dividend date for that was 1742169600. Beta for the stock currently stands at 1.25.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BRKR was down-trending over the past week, with a drop of -4.70%, but this was down by -22.28% over a month. Three-month performance dropped to -38.52% while six-month performance fell -42.51%. The stock lost -56.75% in the past year, while it has lost -38.11% so far this year. A look at the trailing 12-month EPS for BRKR yields 0.76 with Next year EPS estimates of 2.98. For the next quarter, that number is 0.44. This implies an EPS growth rate of 7.74% for this year and 14.93% for next year. EPS is expected to grow by 12.38% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -9.69%.
Float and Shares Shorts:
At present, 151.68 million BRKR shares are outstanding with a float of 102.90 million shares on hand for trading. On 2025-03-31, short shares totaled 8.53 million, which was 561.99998 higher than short shares on 1740700800. In addition to Dr. Frank H. Laukien Ph.D. as the firm’s Chairman, CEO & President, Dr. Mark R. Munch Ph.D. serves as its Corporate Executive VP and President of Bruker Nano Group & Corporate.
Institutional Ownership:
Through their ownership of 0.82605004 of BRKR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, BRKR reported revenue of $979600000.0 and operating income of $157000000.0. The EBITDA in the recently reported quarter was $206200000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BRKR since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BRKR analysts setting a high price target of 80.0 and a low target of 45.0, the average target price over the next 12 months is 60.13. Based on these targets, BRKR could surge 120.51% to reach the target high and rise by 24.04% to reach the target low. Reaching the average price target will result in a growth of 65.74% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.39703 being high and $2.37713 being low. For BRKR, this leads to a yearly average estimate of $2.38708. Based on analyst estimates, the high estimate for the next quarter is $0.61 and the low estimate is $0.51. The average estimate for the next quarter is thus $0.56.
